the aid library

LIST OPTIONS

Filter

1935

Sort by:

Direction:

Download (106)

View PDF (156)

Requirements and technical specifications of personal protective equipment (PPE) for the novel coronavirus (2019-ncov) in healthcare settings

Pan American Health Organization PAHO (2020) C_WHO

In December 2019 a novel coronavirus (2019-nCoV) was identified as the causative agent of a severe acute respiratory illness among people exposed in a seafood market in Wuhan, China; • Human-to-human transmission has been documented, including in healthcare workers, and aerosol-generating procedur... more

Download (95)

View PDF (149)

Guidelines for the use of non-pharmaceutical measures to delay and mitigate the impact of 2019-nCoV

European Centre for Disease Prevention and Control ECDC (2020) C1

This document provides guidance on the application of non-pharmaceutical countermeasures to minimise the spread of the 2019 novel coronavirus (2019-nCoV) in the population. Some of the measures proposed refer specifically to certain phases of the epidemic (containment or mitigation phases), and can ... more

Download (123)

View PDF (174)

Ethiopia Country Refugee Response Plan - The integrated response plan for refugees from Eritrea, Sudan, South Sudan and Somalia 2020

UN High Commissioner for Refugees UNHCR (2020) C1

Refugee protection in the country is provided within the framework of these international and national refugee laws as well as the core international human rights treaties that have been ratified by the country. Continued insecurity within neighbouring states has resulted in sustained refugee moveme... more

Download (199)

View PDF (189)

2019 Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline
recommended

World Health Organization WHO (2019) C_WHO

Of the 50 antibiotics in the pipeline, 32 target WHO priority pathogens but the majority have only limited benefits when compared to existing antibiotics. Two of these are active against the multi-drug resistant Gram-negative bacteria, which are spreading rapidly and require urgent solutions. Gr... more

Download (136)

View PDF (155)

National Action Plan for Combating Antimicrobial Resistance In the Hashemite Kingdom of Jordan (2018-2022)

Ministry of Health Jordan (2018) C_WHO

The objectives of NAP are aligned with the global action plan based on national needs and priorities. The emphasis is on One Health approach with all sectors especially human health, animal health and environment contributing towards minimizing the emergence and impact of AMR in Jordan.

Download (135)

View PDF (175)

National Action Plan to Tackle Antimicrobial Resistance in the Republic of Tajikistan

Republic of Tajikistan (2018) C_WHO

The present National action plan on antimicrobial resistance (AMR) with component of antimicrobial consumption (AMC) covering both human and agriculture sectors was developed based on the World Health Organization's (WHO) Global plan on AMR dated 2015. With the purpose to develop this plan, in May 2... more

Download (121)

View PDF (170)

ECDC/EFSA/EMA second joint report on the integratedanalysis of the consumption of antimicrobial agents andoccurrence of antimicrobial resistance in bacteria fromhumans and food-producing animals

European Centre for Disease Prevention and Control (ECDC), European Food Safety Authority (EFSA) andEuropean Medicines Agency (EMA) (2017) C_CDC

The second ECDC/EFSA/EMA joint report on the integrated analysis of antimicrobial consumption (AMC) and antimicrobial resistance (AMR) in bacteria from humans and food-producing animals addressed data obtained by the Agencies’ EU-wide surveillance networks for 2013–2015. AMC in both sectors, exp... more

Download (149)

View PDF (150)

Saudi Arabia National Action Plan on combating AMR

Ministry of Health Saudi Arabia (2017) C2

This action plan for the Kingdom Saudi Arabia to combat antimicrobial resistance has been formulated in the line of the WHO five objectives. It addresses the need for effective “one health” approach involving coordination among numerous national sectors and actors, including human and veterinary... more

Download (100)

View PDF (842)

Antimicrobial resistance in the WHO African region: current status and roadmap for action

Essack S.Y., A.T. Desta, R.E. Abotsi et al. Journal of Public Health (2016) C2

The escalating antimicrobial resistance (AMR) pandemic is a global public health threat with extensive health, economic and societal implications. Resistance emerges because of selection pressure from rational and indiscriminate antimicrobial use in human health as well as in the veterinary, agricul... more

Download (128)

View PDF (821)

Introducing One Health to the ethical debate about zoonontic diseases in Southeast Asia

Capps, B.; M.M. Bailey, D. Bickford et al. Bioethics (2015) CC

Bioethics 519 (online) doi:10.1111/bioe.12145 Volume 29 Number 8 2015 pp. 488–596; Pandemic plans recommend phases of response to an emergent infectious disease (EID) outbreak, and are primarily aimed at preventing and mitigating human-to-human transmission. These plans carry presumptive weight ... more

Download (191)

View PDF (178)

Clinical Management of Yellow Fever in the Region of the Americas. Experiences and Recommendations for Health Services

Pan American Health Organisation PAHO (2023) CC

The waves of yellow fever transmission in the Region of the Americas in 2016–2018 involved the largest number of human and epizootic cases to be reported in several decades. Yellow fever is a serious viral hemorrhagic disease that poses a challenge for health professionals. It requires early recog... more

Download (107)

View PDF (123)

Coronavirus disease 2019 (COVID-19) Frequently Asked Questions

Centre for Respiratory Diesease and Meningitis, South Africa Department: Health Republic of South Africa (2020) C2

1. What is COVID-19? 2. Who is at most risk for COVID-19? 3. What is the risk of COVID-19 infection in humans in South Africa? 4. How is COVID-19 transmitted? 5. What are the signs and symptoms of COVID-19 infection in humans? 6. How is COVID-19 diagnosed? 7. How is COVID-19 infection ... more

Download (614)

View PDF (1032)

WHO Expert Consultation on Rabies. 3rd report

Abela-Ridder, B. World Health Organisation (WHO) (2018) C_WHO

WHO TRS N°1012. Key updates include: (i) surveillance strategies, including cross-sectoral linking of systems and suitable diagnostics; (ii) the latest recommendations on human and animal immunization; (iii) palliative care in lowresource settings; (iv) risk assessment to guide management of bite... more

Download (126)

View PDF (194)

Primary Protection: Enhancing Health Care Resilience for a Changing Climate

Robin G. and J. Balbus (2014) CC

Best Practices Report.PART 1 Primary Protection: Enhancing Health Care Resilience for a Changing Climatei Primary Protection: EnhancingU.S. Department of Health and Human Services

Download (112)

View PDF (959)

Changing food systems and infectious disease risks in low-income and middle-income countries

Waage, J.; D. Grace; E.M. Févre; et al. The Lancet Planetary Health (2022) CC

Lancet Planet Health 2022;6: e760–68 The emergence of COVID-19 has drawn the attention of health researchers sharply back to the role that food systems can play in generating human disease burden. But emerging pandemic threats are just one dimension of the complex relationship between agriculture... more

Download (247)

View PDF (309)

Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health

World Health Organization WHO (2021) C_WHO

8 January 2021 Sequencing enabled the world to rapidly identify SARS-CoV-2 and develop diagnostic tests and other tools for outbreak management. Continued genome sequencing supports the monitoring of the disease’s spread and evolution of the virus. Accelerated integration of genome sequencing int... more

Download (325)

View PDF (461)

Protecting people and animals from disease threats

Food and Agriculture Organization (FAO) (2018) C1

The Global Health Security Agenda programme develops national capacity to prevent zoonotic and non-zoonotic diseases while quickly and effectively detecting and controlling diseases when they do emerge. The Emerging Pandemic Threats programme improves national capacity to pre-empt the emergence and ... more

Download (229)

View PDF (151)

Barbados National Action Plan on Combatting Antimicrobial Resistance 2017-2022

MINISTRY OF HEALTH, BARBADOS (2017) C_WHO

Barbados currently has a rudimentary framework and capacity to address the issue of antimicrobial resistance. There however needs to be coordination of efforts and improvement in areas where gaps have been identified.Actions required include improved antibiotic stewardship in healthcare settings, pr... more

Download (125)

View PDF (651)

Buruli ulcer: wound care and rehabilitation

Frimpong, M.; F. S.Sarfo, M. Sarpong Duah, et al. Dove Medical Press Limited (2016) C1

Buruli ulcer caused by Mycobacterium ulcerans is a neglected tropical disease characterized by extensive ulceration involving predominantly the upper and lower limbs of patients. The disease is common in rural tropical communities in West and Central Africa, where access to proper health care is lim... more

Download (41)

View PDF (44)

Mpox Testing Strategy - November 2024

Africa Center for Disease Control and Prevention (2024) CC

Mpox is an emerging zoonotic disease caused by the mpox virus, a member of the Orthopoxvirus genus closely related to the variola virus that causes smallpox. Mpox was first discovered in 1958 when outbreaks of a pox-like disease occurred in monkeys kept for research. The first human case was recorde...d in 1970 in the Democratic Republic of the Congo (DRC) during a period of intensified effort to eliminate smallpox and since then the infection has been reported in a number of African countries. Mpox can spread in humans through close contact, usually skin-to-skin contact, including sexual contact, with an infected person or animal, as well as with materials contaminated with the virus such as clothing, beddings and towels, and respiratory droplets in prolonged face to face contact. People remain infectious from the onset of symptoms until all the lesions have scabbed and healed. The virus may spread from infected animals through handling infected meat or through bites or scratches. Diagnosis is confirmed by polymerase chain reaction (PCR) testing of material from a lesion for the virus’s DNA. Two separate clades of the mpox virus are currently circulating in Africa: Clade I, which includes subclades Ia and Ib, and Clade II, comprising subclades IIa and IIb. Clade Ia and Clade Ib have been associated with ongoing human-to-human transmission and are presently responsible for outbreaks in the Democratic Republic of the Congo (DRC), while Clade Ib is also contributing to outbreaks in Burundi and other countries. In 2022‒2023 mpox caused a global outbreak in over 110 countries, most of which had no previous history of the disease, primarily driven by human-to-human transmission of clade II through sexual contact. In just over a year, over 90,000 cases and 150 deaths were reported to the WHO. For the second time since 2022, mpox has been declared a global health emergency as the virus spreads rapidly across the African continent. On 13 Aug 2024, Africa CDC declared the ongoing mpox outbreak a Public Health Emergency of Continental Security (PHECS), marking the first such declaration by the agency since its inception in 2017.7 This declaration empowered the Africa CDC to lead and coordinate responses to the mpox outbreak across affected African countries. On August 14, 2024, the WHO declared the resurgence of mpox a Public Health Emergency of International Concern (PHEIC) emphasizing the need for coordinated international response. As of August 2024, Mpox has expanded beyond its traditional endemic regions, with new cases reported in countries including Sweden, Thailand, the Philippines, and Pakistan. Sweden has confirmed its first case of Clade 1 variant, which has been rapidly spreading in Africa, particularly in DRC. The emergence of this new variant raises concerns about its potential for higher lethality and transmission rates outside Africa. more

2019 Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline recommended

2019 Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline
recommended